Pure Global AI
NCT06417554Not yet recruiting

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

A Phase IB /II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection With or Without Antitumor Therapy in Subjects With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
SHR-A2102
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Timeline & enrollment
Phase
Phase 1/2
Start date
May 01, 2024
End date
Jul 01, 2027
Enrollment
80 participants
Primary outcome

RP2D,Incidence and severity of AE；,ORR

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102
 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the
 reasonable dosage of SHR-A2102 for Advanced Solid Tumors.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06417554
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06417554 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.